A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors

Annals of Oncology

Volumn 17, Issue 11, 2006, Pages 1709-1717

  Gore, Lia ^a,e   Holden, S N ^a   Cohen, R B ^b   Morrow, M ^a   Pierson, A S ^a   O'Bryant, C L ^a   Persky, M ^a   Gustafson, D ^a   Mikule, C ^a   Zhang, S ^c   Palmer, P A ^c,d   Eckhardt, S G ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Capecitabine; Farnesyltransferase inhibitor; Pharmacokinetics; Phase I; Tipifarnib

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; CHAPERONE; CISPLATIN; FLUOROURACIL; FOLINIC ACID; NAVELBINE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TAMOXIFEN; TIPIFARNIB;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER REGRESSION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LIVER DYSFUNCTION; MALE; NAUSEA; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; ALKYL AND ARYL TRANSFERASES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG TOXICITY; FEMALE; FLUOROURACIL; HSP40 HEAT-SHOCK PROTEINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PROTEIN ISOPRENYLATION; QUINOLONES;

EID: 33750586717     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl282     Document Type: Article

References (35)

1. Kato K, Cox A, Hisaka M et al. Isoprenoid addition of the ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 1992; 89: 6403-6407.
2. End D, Skrzat S, Devine A et al. R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI): Biochemical and cellular effects in H-ras and K-ras dominant systems. Proc Am Assoc Cancer Res 1998; 39: 270.
3. End DW, Smets G, Todd AV et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001; 61: 131-137.
4. Crul M, deKlerk GJ, Swart M et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2002; 20: 2726-2735.
5. Piccart-Gebhart M, Branle D, de Valeriola M et al. A phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel: A promising combination in patients (PTS) with solid tumors. Proc Annu Meet Am Soc Clin Oncol 2001; 20: 318.
6. Zujewski J, Horak ID, Bol CJ et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000; 18: 927-941.
7. Adjei AA, Mauer A, Bruzek LM et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 1760-1766.
8. Rao S, Cunningham D, De Gramont A et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 2004; 22: 3950-3957.
9. MacDonald JS, McCoy S, Whitehead RP et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A southwest oncology group (SWOG 9924) study. Invest New Drugs 2005; 23: 485-487.
10. Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438.
11. Cohen SJ, Ho L, Ranganathan S et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 2003; 21: 1301-1306.
12. Rosenberg JE, von der Maase H, Seigne JD et al. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer 2005; 103: 2035-2041.
13. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissues. Eur J Cancer 1998; 34: 1274-1281.
14. Schuller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-297.
15. Blum J, Jones S, Buzdar A et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-493.
16. Verslype C, Van Steenbergen W, Humblet Y et al. Phase I trial of 5-FU/LV in combination with the farnesyltransferase inhibitor (FTI) R115777. Proc Am Soc Clin Oncol 2001; abstract 681.
17. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Ann Biochem 1976; 72: 248-254.
18. Johnston SRD, Hickish T, Ellis P et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003; 21: 2492-2499.
19. Britten CD, Rowinsky EK, Soignet S et al. A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-788,123 in patients with solid malignancies. Clin Cancer Res 2001; 7: 3894-3903.
20. Eskens FALM, Awada A, Cutler DL et al. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 2001; 19.
21. Schellens JH, deKlerk G, Swart M et al. Phase I and pharmacologic study with the novel farnesyltransferase inhibitor R115777. Proc Am Soc Clin Oncol 2000; abstract 184.
22. Adjei AA, Croghan GA, Erlichman C et al. A phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 2003; 9: 2520-2526.
23. Sparreboom A, Kehrer DF, Mathijssen RH et al. Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor. Br J Cancer 2004; 90: 1508-1515.
24. Cortes J, Albitar M, Thomas D et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003; 101: 1692-1697.
25. Karp JE, Lancet JE, Kaufmann SH et al. Clinical and biological activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase I clinical-laboratory correlative trial. Blood 2001; 97: 3361-3369.
26. Lara PN, Law LY, Wright JJ et al. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced solid tumors: A phase I California Consortium Trial. Anticancer Drugs 2005; 16: 317-321.
27. Punt CJA, Van Maanen L, Bol CJJG et al. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs 2001; 12.
28. Johnson J. Clinical investigator's brochure. In Johnson & Johnson Pharmaceutical Research and Development (JJPR) (ed.): Development Edition. JJPR. Titusville, NJ 2002.
29. Patnaik A, Eckhardt SG, Izbicka E et al. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies. Clin Cancer Res 2003; 9: 4761-4771.
30. Gore L, Basche M, Holden SN et al. A phase I pharmacological and biological study of Sarasar (lonafarnib, SCH66336), cisplatin and gemcitabine in patients with advanced solid tumors. Eur J Cancer 2004; 2: Abstract 30.
31. Whyte DB, Kirschmeier P, Hockenberry TN et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997; 272: 14459-14464.
32. Caraglia M, Budillon A, Tagliaferri P et al. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: Preclinical and clinical implications. Curr Drug Targets 2005; 6: 301-323.
33. Sepp-Lorenzino L, Ma Z, Rands E et al. A peptidomimetic inhibitor of farnesyl protein transferase blocks anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995; 55: 5302-5309.
34. Jiang K, Coppola D, Crespo NC et al. The phosphoinositide 3-OH kinase/ AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 2000; 20: 139-148.
35. Lebowitz PF, Prendergast GC. Non-ras targets of farnesyltransferase inhibitors: Focus on Rho. Oncogene 1998; 17: 1439-1445.